发明名称 |
Von willebrand factor- and factor VIII-polymer conjugates having a releasable linkage |
摘要 |
The present invention provides von Willebrand Factor-polymer conjugates and Factor VIII-polymer conjugates, each having a releasable linkage. Methods of making conjugates, methods for administering conjugates, are also provided. |
申请公布号 |
US9493544(B2) |
申请公布日期 |
2016.11.15 |
申请号 |
US201213620285 |
申请日期 |
2012.09.14 |
申请人 |
Nektar Therapeutics;Baxalta Incorporated;Baxalta GmbH |
发明人 |
Bossard Mary J.;Stephenson Gayle;Fang Zhihao;Zappe Harold;Mitchell Stacy;Zhang Ping;Scheiflinger Friedrich;Turecek Peter;Siekmann Juergen;Varadi Katalin;Gritsch Herbert |
分类号 |
C07K14/755;C07K14/745;C07K17/08;A61K47/48 |
主分类号 |
C07K14/755 |
代理机构 |
McDermott Will & Emery LLP |
代理人 |
Evans Susan T.;Wilson Mark A.;McDermott Will & Emery LLP |
主权项 |
1. A method of treating a bleeding disorder in a subject, said method comprising administering a therapeutically effective amount of a modified protein having an extended in-vivo half life over the unmodified parent protein, wherein the unmodified parent protein is either a von Willebrand Factor moiety or a Factor VIII moiety and the modified protein is a conjugate having a formula:wherein:
POLY1 is a first water-soluble polymer; POLY2 is a second water-soluble polymer; X1 is a first spacer moiety; X2 is a second spacer moiety; Hα is an ionizable hydrogen atom; R1 is H or an organic radical; R2 is H or an organic radical; (a) is either zero or one; (b) is either zero or one; Re1, when present, is a first electron altering group; Re2, when present, is a second electron altering group; Y1 is O or S; and Y2 is O or S, such thatfrom the formula is a releasable linkage that is selected from a carbamate linkage, a thiocarbamate linkage, and a dithiocarbamate linkage; and
(vWF/F8) is a residue of an amine-containing biologically active agent that is either a von Willebrand Factor moiety or a Factor VIII moiety. |
地址 |
San Francisco CA US |